FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Axsome Therapeutics, Inc. (AXSM) announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.A final decision from the regulatory body is expected on Jan. 31, 2025. The FDA has designated the NDA resubmission as a Class 2 resubmission.Shares of AXSM were up 6.6% on Sept. 4 following the announcement of the news.Year to date, shares of Axsome have rallied 20.1% against the industry’s decrease of 0.9%.Image Source: Zacks Invest ...